Modulation of Thymosin Beta-4 in Skin
AssigneeAvon Products, Inc.
InventorsYing Cheng, Qian Zheng, Russell J. Wyborski
Life of this patent
Estimating the term…
Abstract
Methods for preventing, ameliorating, or reducing dermatological signs of inflammation are provided which employ active agents, other than a retinoid, that stimulate thymosin beta-4 expression in the skin and inhibit production of pro-inflammatory chemokines and/or cytokines. Also provided are methods for screening for substances which stimulate thymosin beta-4 expression levels and the methods of using active agents identified by the screening protocol in the treatment of skin.
Claims16
A method for inhibiting the inflammatory response of human skin comprising topically applying to an area of the skin in need thereof an effective amount of an active agent, other than a retinoid, that stimulates human thymosin beta-4 expression and inhibits inflammatory response, for a time sufficient to inhibit the inflammatory response of said human skin.
A method for identifying at least one active agent useful for inhibiting the inflammation response of skin comprising assaying at least one candidate substance for ability to stimulate thymosin beta-4 expression in at least one of a dermal fibroblast or a epidermal keratinocyte by incubating human dermal fibroblasts or human epidermal keratinocytes with said candidate substance and subsequently measuring the levels of mRNA encoding thymosin beta-4.
A cosmetic composition for improving the aesthetic appearance of human skin comprising a cosmetically acceptable vehicle, and an effective amount of an active agent, other than a retinoid, that inhibits skin inflammation and upregulates thymosin beta-4, wherein said effective amount of active agent comprises from about 0.00001% to about 90% by weight of the total composition.
Dependencies are inferred from the claim text.